作者
Norbert Galldiks, Veronika Dunkl, Gabriele Stoffels, Markus Hutterer, Marion Rapp, Michael Sabel, Guido Reifenberger, Sied Kebir, Franziska Dorn, Tobias Blau, Ulrich Herrlinger, Peter Hau, Maximilian I Ruge, Martin Kocher, Roland Goldbrunner, Gereon R Fink, Alexander Drzezga, Matthias Schmidt, Karl-Josef Langen
发表日期
2015/4
期刊
European journal of nuclear medicine and molecular imaging
卷号
42
页码范围
685-695
出版商
Springer Berlin Heidelberg
简介
Purpose
The follow-up of glioblastoma patients after radiochemotherapy with conventional MRI can be difficult since reactive alterations to the blood–brain barrier with contrast enhancement may mimic tumour progression (i.e. pseudoprogression, PsP). The aim of this study was to assess the clinical value of O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) PET in the differentiation of PsP and early tumour progression (EP) after radiochemotherapy of glioblastoma.
Methods
A group of 22 glioblastoma patients with new contrast-enhancing lesions or lesions showing increased enhancement (>25 %) on standard MRI within the first 12 weeks after completion of radiochemotherapy with concomitant temozolomide (median 7 weeks) were additionally examined using amino acid PET with 18F-FET. Maximum and mean tumour-to-brain ratios (TBRmax, TBRmean …
学术搜索中的文章
N Galldiks, V Dunkl, G Stoffels, M Hutterer, M Rapp… - European journal of nuclear medicine and molecular …, 2015